002287 奇正藏药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入1,522,9443.48%2,337,9702,045,1522,044,7891,770,486
减:营业总成本1,201,0472.99%1,858,5031,628,6741,555,9731,374,825
    其中:营业成本270,261-0.24%418,375323,315324,140265,342
               财务费用34,508-18.67%53,86750,22939,92219,476
               资产减值损失587-342.33%(1,179)(1,401)(2,454)(16,061)
公允价值变动收益64,650-5.22%105,13737,074(3,429)20,693
投资收益(5,962)-155.74%(4,822)28,780(33,652)305,893
    其中:对联营企业和合营企业的投资收益(4,274)-4.66%(6,466)1,888(54,907)293,361
营业利润491,8669.17%657,025646,383521,541790,206
利润总额472,2456.98%646,244644,413519,202787,914
减:所得税费用48,6823.43%64,87565,23549,56077,088
净利润423,5637.40%581,370579,178469,643710,826
减:非控股权益44-95.55%(911)(2,021)(2,900)(5,050)
股东净利润423,5197.66%582,281581,199472,542715,876

市场价值指针
每股收益 (元) *0.7916.63%1.0981.0970.8921.354
每股派息 (元) *0.2200.00%0.6000.4800.3900.590
每股净资产 (元) *8.39319.44%7.4076.7646.0395.723
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容